In contrast to melanomas, BRAF-driven colorectal cancers require EGFR inhibition to prevent an activation of the compensatory signaling cascade, and are usually treated by combined administration of anti-EGFR antibodies and antagonists of mutated BRAF [97]. This evidence concerns the gene EGFR and melanoma.